Suppr超能文献

结直肠肝转移灶对99m锝标记的大颗粒聚合白蛋白(99mTc-MAA)的摄取与选择性体内放射治疗(SIRT)后反应的关系。

Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT).

作者信息

Dhabuwala Atul, Lamerton Prue, Stubbs Richard S

机构信息

Wakefield Gastroenterology Centre, Wakefield Hospital, Wellington, New Zealand.

出版信息

BMC Nucl Med. 2005 Dec 23;5:7. doi: 10.1186/1471-2385-5-7.

Abstract

BACKGROUND

SIRT is an emerging treatment for liver tumours which relies on the selective uptake by tumour of 90Y microspheres following hepatic arterial injection. Response rates of around 90% are reported. Hepatic arterial injection of MAA gives an indication of the expected distribution of 90Y microspheres within the liver. This study sought to determine if the MAA scan could be predictive of subsequent tumour response.

METHODS

58 patients with colorectal hepatic metastases received SIRT. All had pre-treatment MAA planar images and CT scans which were retrospectively reviewed. Tumours were qualitatively considered "cold", "equivocal" or "hot" based on MAA uptake and the ratio of uptake in tumour and normal liver tissue was calculated (TNR). Following SIRT (which included the administration of hepatic arterial Angiotensin 2) tumour response was assessed by CEA changes one to two months after treatment and by serial CT.

RESULTS

Uptake was classified as "hot" in 37 patients (Group 1) and "equivocal" or "cold" in 21 (Group 2). CEA levels fell dramatically in over 90% of patients. The falls were not significantly different between the groups. There was no correlation between TNR and tumour response based on CEA changes (r2 = 0.004). CT responses after 3 months were not different in the 2 Groups.

CONCLUSION

The pattern of MAA uptake by colorectal liver tumours after arterial injection is not a predictor of tumour response after treatment by SIRT. The results suggest the doses of 90Y microspheres used may be greater than is necessary.

摘要

背景

选择性体内放射疗法(SIRT)是一种新兴的肝癌治疗方法,它依赖于肝动脉注射后肿瘤对钇-90微球的选择性摄取。据报道,缓解率约为90%。肝动脉注射大颗粒聚合人血清白蛋白(MAA)可显示钇-90微球在肝脏内的预期分布情况。本研究旨在确定MAA扫描是否能够预测后续的肿瘤反应。

方法

58例结直肠癌肝转移患者接受了SIRT治疗。所有患者均有治疗前的MAA平面图像和CT扫描,对其进行回顾性分析。根据MAA摄取情况,将肿瘤定性为“冷”“不明确”或“热”,并计算肿瘤与正常肝组织的摄取比值(TNR)。在SIRT治疗后(包括肝动脉注射血管紧张素2),通过治疗后1至2个月的癌胚抗原(CEA)变化以及系列CT评估肿瘤反应。

结果

37例患者(第1组)的摄取被分类为“热”,21例患者(第2组)的摄取为“不明确”或“冷”。超过90%的患者CEA水平显著下降。两组之间的下降情况无显著差异。基于CEA变化,TNR与肿瘤反应之间无相关性(r2 = 0.004)。两组在3个月后的CT反应无差异。

结论

动脉注射后结直肠癌肝转移瘤的MAA摄取模式不能预测SIRT治疗后的肿瘤反应。结果表明,所使用的钇-90微球剂量可能大于所需剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2534/1360059/39a5d6a7859d/1471-2385-5-7-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验